Related references
Note: Only part of the references are listed.What is the prognosis for new centrally-acting anti-obesity drugs?
David J. Heal et al.
NEUROPHARMACOLOGY (2012)
Biology's response to dieting: the impetus for weight regain
Paul S. MacLean et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2011)
FGF15/19 Regulates Hepatic Glucose Metabolism by Inhibiting the CREB-PGC-1α Pathway
Matthew J. Potthoff et al.
CELL METABOLISM (2011)
Lowering Bile Acid Pool Size with a Synthetic Farnesoid X Receptor (FXR) Agonist Induces Obesity and Diabetes through Reduced Energy Expenditure
Mitsuhiro Watanabe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity
F. D. Christopoulou et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2011)
FGF19 Regulates Cell Proliferation, Glucose and Bile Acid Metabolism via FGFR4-Dependent and Independent Pathways
Ai-Luen Wu et al.
PLOS ONE (2011)
FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis
Serkan Kir et al.
SCIENCE (2011)
Adaptive thermogenesis in humans
M. Rosenbaum et al.
INTERNATIONAL JOURNAL OF OBESITY (2010)
TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Charles Thomas et al.
CELL METABOLISM (2009)
Cholesterol Feeding Prevents Hepatic Accumulation of Bile Acids in Cholic Acid-Fed Farnesoid X Receptor (FXR)-Null Mice: FXR-Independent Suppression of Intestinal Bile Acid Absorption
Masaaki Miyata et al.
DRUG METABOLISM AND DISPOSITION (2009)
Pharmacotherapy of obesity: emerging drugs and targets
Ranjan Chakrabarti
EXPERT OPINION ON THERAPEUTIC TARGETS (2009)
FGF15/FGFR4 Integrates Growth Factor Signaling with Hepatic Bile Acid Metabolism and Insulin Action
Dong-Ju Shin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Fibroblast Growth Factor-19, a Novel Factor That Inhibits Hepatic Fatty Acid Synthesis
Sushant Bhatnagar et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Blockade of the Endocannabinoid System for the Reduction of Cardiometabolic Risk Factors
Frederick F. Samaha et al.
OBESITY (2009)
Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders
Stefano Fiorucci et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Reduction of JNK1 expression with antisense oligonucleotide improves adiposity in obese mice
Xing Xian Yu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2008)
Insights into energy balance from doubly labeled water
D. A. Schoeller
INTERNATIONAL JOURNAL OF OBESITY (2008)
FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet-induced fatty liver
Xinqiang Huang et al.
DIABETES (2007)
Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance
Cheol Soo Choi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Reduction of low molecular weight protein-tyrosine phosphatase expression improves hyperglycemia and insulin sensitivity in obese mice
Sanjay K. Pandey et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Drug treatments for obesity: orlistat, sibutramine, and rimonabant
Raj S. Padwal et al.
LANCET (2007)
Understanding and addressing the epidemic of obesity: An energy balance perspective
James O. Hill
ENDOCRINE REVIEWS (2006)
Identification of a hormonal basis for gallbladder filling
Mihwa Choi et al.
NATURE MEDICINE (2006)
Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2
DB Savage et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation
M Watanabe et al.
NATURE (2006)
Antiobesity therapy: Emerging drugs and targets
SK Das et al.
CURRENT MEDICINAL CHEMISTRY (2006)
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
T Inagaki et al.
CELL METABOLISM (2005)
Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice
XX Yu et al.
HEPATOLOGY (2005)
CB1 cannabinoid receptor-mediated modulation of food intake in mice
JL Wiley et al.
BRITISH JOURNAL OF PHARMACOLOGY (2005)
Fibroblast growth factor 19 increases metabolic rate I and reverses dietary and leptlin-deficient diabetes
L Fu et al.
ENDOCRINOLOGY (2004)
Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis
JA Holt et al.
GENES & DEVELOPMENT (2003)
Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice
CR Trillou et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2003)
Very-low-calorie diets and sustained weight loss
WHM Saris
OBESITY RESEARCH (2001)
Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4
CD Yu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
